Ilona J. M. Bisschop

Ilona J. M. Bisschop

Auto-generated profile, based on publicly available information

Ilona J. M. Bisschop

Janssen Vaccines & Prevention BV, 2333 CN Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FMFin J. Milder
Fin J. Milder
MJMandy Jongeneelen
Mandy Jongeneelen
TRTina Ritschel
Tina Ritschel
PBPascale Bouchier
Pascale Bouchier
IBIlona J. M. Bisschop
Ilona J. M. Bisschop
JLJohannes PM Langedijk
Johannes PM Langedijk
Significance: Influenza hemagglutinin (HA) is a prototypical class I fusion protein and a major component of current flu vaccines. HA is a metastable glycoprotein and undergoes conformational changes to the so-called postfusion state. Stabilization of the prefusion conformations of fusion proteins has proven to be a key success factor for the induction of efficacious immune response and stabilization has become a grand challenge in structural vaccinology. The study shows that three stabilizing mutations in two important pH-sensitive switch regions involved in the early refolding process impede refolding of the prefusion HA. Based on the substitutions of these highly conserved and buried HA residues a generally applicable stabilization strategy for all subtypes of group 1 and 2 influenza A HA was developed.